Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25827946 | 0.79 | HRH3 (0.43) | ESR1HRH3CASRTHRATHRB | |
| SCHEMBL25826615 | 0.79 | SMN1; SMN2 (0.38) | FFAR1MAPTABCB11CYP3A4ADRA2B | |
| SCHEMBL25826612 | 0.78 | FFAR1 (0.37) | ESR1FFAR1THRATHRB | |
| SCHEMBL24038030 | 0.73 | ESR1 (0.47) | ESR1MAPTGAATHRATHRB | |
| SCHEMBL14670707 | 0.69 | ESR1 (0.50) | ESR1MAPTGAAADRA2BTHRA | |
| SCHEMBL25827939 | 0.69 | ESR1 (0.40) | ESR1HRH3MAPTTHRATHRB | |
| SCHEMBL11792842 | 0.68 | CYP3A4 (0.43) | HRH3MAPTGAAABCB11CYP3A4 | |
| SCHEMBL7182245 | 0.67 | HRH3 (0.47) | HRH3 | |
| SCHEMBL20325268 | 0.67 | HRH3 (0.39) | HRH3 | |
| SCHEMBL28984108 | 0.67 | HRH3 (0.44) | HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | ESR1 1503/4885HRH3 2453/4885FFAR1 3820/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | ESR1 1503/4885HRH3 2453/4885FFAR1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.